We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
EpiCept has announced that LidoPAIN SP, a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound, did not meet its primary endpoints in a Phase III trial in Europe.
Perrigo announced that its Perrigo Israel Pharmaceuticals subsidiary has been granted tentative approval from the FDA for its abbreviated new drug application (ANDA) for clobetasol propionate topical foam, 0.05 percent.
FermaVir Pharmaceuticals has announced that preclinical studies show that its compound for shingles inhibits viral infections quickly, and that when administered orally, FV-100 shows dose-dependent pharmacokinetics.
Aktiv-Dry has been awarded an $850,000 Small Business Innovation Research (SBIR) grant from the National Institute on Drug Abuse of the NIH to develop an inhalable nicotine vaccine.
Exelixis has submitted an investigational new drug (IND) application to the FDA to begin Phase I trials of XL228, designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases.
A Swedish HIV vaccine study conducted by researchers at Karolinska Institutet, Karolinska University Hospital and the Swedish Institute for Infectious Disease Control has produced positive results.
Allos Therapeutics has enrolled the first patient in PROPEL, a multicenter Phase II study of the company's next-generation antifolate, PDX (pralatrexate), with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).